Income StatementBalance SheetCash FlowBusiness Segments
Johnson & Johnson logo

Johnson & Johnson Business Segments

Business, geographic, and product segment breakdowns

Johnson & Johnson generates $92.1B in annual revenue across 2 key segments: Innovative Medicine ($59.0B), and Medical Devices ($33.2B). Based on the Q3 2025 filing.

Innovative Medicine (TTM)$59.0BMedical Devices (TTM)$33.2B
Latest FilingQ3 2025
Report Date2025-10-22
Market Cap$579.15B
P/E Ratio23.06
ROE33.62%

Business Segments

Goodwill (Note 3)

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Medical Devices$33.5B$33.7B$33.5B$33.6B$33.8B$33.8B
Pharmaceutical$10.8B$11.1B$10.7B$10.9B$14.3B$14.3B

Goodwill, related to acquisitions

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Pharmaceutical$273.0M$57.0M$20.0M$0.0$2.9B-$30.0M
Medical Devices$7.5B$73.0M$2.0M$0.0$0.0$0.0

Goodwill, Written off Related to Sale of Business Unit

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Pharmaceutical$0.0$0.0$0.0$0.0$0.0$0.0
Medical Devices$56.0M$0.0$0.0$29.0M$0.0$0.0

Currency translation/Other

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Pharmaceutical-$57.0M$287.0M-$440.0M$215.0M$543.0M-$28.0M
Medical Devices-$20.0M$132.0M-$181.0M$82.0M$230.0M-$11.0M

Reversal of fee expense

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Consumer———$7.0B$0.0$0.0

Sales to customers (Note 9)

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Innovative Medicine$14.5B$14.6B$14.3B$13.9B$15.2B$15.6B
Medical Devices$8.0B$7.9B$8.2B$8.0B$8.5B$8.4B

Percent Change (as a percent)

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Innovative Medicine0.160.19-0.090.220.240.21
Medical Devices0.160.26—0.160.230.21

Cost of products sold

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Innovative Medicine$3.6B$3.5B$3.5B$4.0B$4.0B$3.7B
MedTech$3.2B$3.4B$3.6B$3.3B$3.6B$3.6B

Selling, marketing and administrative expenses

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Innovative Medicine$2.7B$2.5B$3.3B$2.3B$2.8B$2.9B
MedTech$2.7B$2.7B$2.8B$2.7B$2.9B$2.8B

Research and development expense

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Innovative Medicine$2.7B$4.2B$3.7B$2.5B$2.9B$2.9B
MedTech$718.0M$739.0M$1.6B$677.0M$647.0M$728.0M

Other (income) expense, net

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Innovative Medicine$41.0M-$155.0M-$201.0M-$166.0M$14.0M-$368.0M
MedTech$231.0M-$11.0M$84.0M-$60.0M$190.0M$2.0M

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Innovative Medicine$5.5B$4.5B$4.0B$5.2B$5.6B$6.4B
Medical Devices$1.1B$1.1B$72.0M$1.4B$1.2B$1.3B

Amortization

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Innovative Medicine$700.0M$700.0M—$600.0M$800.0M$600.0M
Medical Devices$400.0M$500.0M—$500.0M$500.0M$500.0M

Acquisition related costs

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Innovative Medicine—————$100.0M
MEDTECH$600.0M$300.0M$0.0$100.0M$0.0$100.0M

Restructuring (Note 12)

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Medical Devices$100.0M$28.0M$45.0M$100.0M$100.0M$200.0M
MedTech Surgery Franchise$0.0$0.0——$29.0M$128.0M
Innovative Medicine-$63.0M$19.0M$2.0M$100.0M$0.0$0.0

Gain on sale of security

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
MEDTECH—————$200.0M

Total Assets

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Segments Total——$141.4B$143.8B$162.2B$160.9B
Medical Devices——$84.3B$85.1B$86.7B$86.5B
Innovative Medicine——$57.1B$58.7B$75.5B$74.4B
General Corporate——$38.7B$49.8B$31.2B$31.9B

Additions to Property, Plant & Equipment

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Segments Total$902.0M$973.0M$1.6B$756.0M$1.0B$1.1B
MedTech$581.0M$555.0M$814.0M$480.0M$591.0M$603.0M
Innovative Medicine$321.0M$418.0M$739.0M$276.0M$411.0M$479.0M
General Corporate$74.0M$56.0M$59.0M$39.0M$41.0M$75.0M
Consumer$0.0$0.0$0.0———

Depreciation and Amortization

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Segments Total$1.7B$1.8B$1.8B$1.7B$1.9B$1.7B
Medical Devices$806.0M$818.0M$867.0M$836.0M$842.0M$886.0M
Innovative Medicine$850.0M$932.0M$967.0M$884.0M$1.0B$832.0M
General Corporate$126.0M$96.0M$62.0M$52.0M$60.0M$59.0M
Consumer$0.0$0.0$0.0———

Accrued Rebates Returns And Promotions

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Pharmaceutical——$12.3B———

Long-Lived Assets

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
General Corporate——$1.2B———

Impairment of intangible assets, excluding goodwill

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Innovative Medicine$50.0M$50.0M$50.0M———

Supplies expense

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Innovative Medicine$25.0M$25.0M$25.0M———

Realized gain (loss)

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Innovative Medicine$25.0M$25.0M$25.0M———

Payments to Acquire in Process Research and Development

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
MedTech$125.0M$125.0M$125.0M———

Regulation charge

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Medical Devices$50.0M$50.0M$50.0M———

Products & Services

Sales to customers (Note 9)

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
DARZALEX$5.8B$6.0B$6.2B$6.5B$7.1B$7.3B
Stelara$5.8B$5.4B$4.7B$3.3B$3.3B$3.1B
Tremfya$1.8B$2.0B$1.9B$1.9B$2.4B$2.8B
GENERAL$2.7B$2.7B$2.7B$2.6B$2.8B$2.8B
ADVANCED$2.3B$2.2B$2.3B$2.1B$2.3B$2.3B
CONTACTLENSESOTHER$1.8B$1.9B$1.9B$1.8B$1.9B$2.0B
ERLEADA$1.5B$1.6B$1.6B$1.5B$1.8B$1.9B
INVEGASUSTENNAXEPLIONTRINZATREVICTA$2.1B$2.1B$2.1B$1.8B$2.0B$1.9B
TRAUMA$1.5B$1.5B$1.5B$1.5B$1.5B$1.6B
SPINEOTHER$1.5B$1.4B—$1.3B$1.5B$1.4B
IMBRUVICA$1.5B$1.5B$1.5B$1.4B$1.5B$1.4B
Simponi Simponi Aria$1.1B$1.0B$1.2B$1.3B$1.4B$1.4B
Xarelto$1.2B$1.2B$1.4B$1.4B$1.2B$1.3B
OPSUMIT/OPSYNVI(2)$1.1B$1.2B—$1.0B$1.2B$1.2B
CARVYKTI$373.0M$571.0M$669.0M$738.0M$878.0M$1.0B
UPTRAVI$851.0M$917.0M$931.0M$902.0M$952.0M$968.0M
Remicade$786.0M$839.0M$716.0M$934.0M$910.0M$953.0M
SPRAVATO$541.0M$569.0M$594.0M$639.0M$830.0M$917.0M
HIPS$834.0M$762.0M$836.0M$818.0M$842.0M$811.0M
PREZISTAPREZCOBIXREZOLSTASYMTUZA$876.0M$898.0M$814.0M$806.0M$793.0M$793.0M
EDURAN Trilpivirine$593.0M$661.0M$644.0M$716.0M$720.0M$770.0M
SURGICAL$734.0M$666.0M$730.0M$721.0M$808.0M$765.0M
KNEES$787.0M$704.0M$796.0M$778.0M$779.0M$753.0M
Other$610.0M$583.0M$564.0M$646.0M$618.0M$528.0M
OTHERNEUROSCIENCE$588.0M$562.0M$510.0M$553.0M$541.0M$512.0M
CAPLYTA$0.0$0.0——$422.0M$480.0M
RYBREVANT + LAZCLUZE$138.0M$178.0M—$282.0M$359.0M$395.0M
Tecvayli$269.0M$270.0M$292.0M$302.0M$332.0M$354.0M
CONCERTA Methylphenidate$326.0M$285.0M$317.0M$296.0M$327.0M$281.0M
TALVEY$137.0M$151.0M—$172.0M$212.0M$244.0M
ZYTIGA$330.0M$299.0M$271.0M$250.0M$290.0M$226.0M
Other Oncology$440.0M$501.0M$564.0M$178.0M$185.0M$189.0M
Other Infectious Diseases$121.0M$111.0M$89.0M$82.0M$94.0M$93.0M
Other Immunology$4.0M$2.0M$0.0$2.0M$16.0M$24.0M

Percent Change (as a percent)

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
SPRAVATO191.6%156.3%—111.9%127.2%157.5%
CARVYKTI106.3%172.6%———136.8%
Stelara10.2%-18.9%-8.5%-102.4%-128.8%-123.0%
Tremfya83.0%44.7%—55.0%89.4%121.8%
Simponi Simponi Aria6.2%-53.5%—56.1%85.7%109.5%
TALVEY———83.6%93.0%95.0%
ZYTIGA-35.7%-123.1%—-86.5%-60.3%-75.2%
DARZALEX54.1%61.6%—59.9%69.0%64.6%
Other29.1%57.1%-52.0%18.1%-15.4%-62.7%
ERLEADA90.0%74.9%—32.9%69.0%53.7%
Other Oncology73.8%-52.5%4.2%69.2%39.9%42.1%
CONCERTA Methylphenidate-79.0%-91.7%—-42.6%-20.0%-41.6%
Tecvayli70.4%88.3%—57.0%106.1%40.6%
SURGICAL-4.2%1.6%10.1%11.4%31.3%40.6%
PREZISTAPREZCOBIXREZOLSTASYMTUZA-20.5%-3.5%—-12.8%-39.4%-36.2%
IMBRUVICA-24.3%-17.9%—-29.5%-12.6%-28.4%
INVEGASUSTENNAXEPLIONTRINZATREVICTA-2.1%-1.4%7.5%-37.6%-16.1%-27.1%
EDURAN Trilpivirine19.7%8.0%—20.4%19.2%25.4%
UPTRAVI34.5%48.7%—2.9%43.5%24.3%
KNEES27.5%13.1%—-8.3%-3.0%23.4%
HIPS14.1%2.9%—-9.6%2.1%20.8%
OTHERNEUROSCIENCE-83.2%-73.2%—-83.6%-36.6%-19.2%
Other Infectious Diseases-30.2%-100.8%—-88.7%-212.1%18.6%
Remicade-40.3%-54.9%—-37.3%44.4%16.6%
ADVANCED-17.4%-12.9%—-2.5%6.1%15.4%
CONTACTLENSESOTHER-6.0%14.1%8.4%3.0%15.3%15.3%
Xarelto-15.8%-10.4%47.6%66.6%11.2%14.8%
TRAUMA8.2%8.6%—4.1%4.1%13.6%
GENERAL-6.3%2.0%-0.0%-1.2%11.4%11.7%
OPSUMIT/OPSYNVI(2)———-4.4%18.7%-1.3%
SPINEOTHER-10.0%-5.1%—-32.6%-6.5%0.5%

Product liability contingency, number of claimants

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Talc62370.0062740.0062830.0062850.0070030.0073570.00
Pelvic Meshes6230.006190.005990.005910.005350.005220.00
Opioid3500.003500.003500.003500.003500.003500.00
Elmiron2170.002170.002170.001140.00920.00810.00
Pinnacle Acetabular Cup System910.00910.00910.00910.00860.00780.00
Physiomesh170.00160.00130.00140.00120.00110.00
Asr160.00160.0060.0050.0040.0040.00

Loss contingency accrual, payment percentage

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Opioid0.700.700.750.700.800.80

Number of open cases

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Opioid———325.00-35.00-5.00

Selling, marketing and administrative expenses

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Shipping and Handling$225.0M$225.0M$225.0M———

Sales to Customers

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
ELECTROPHYSIOLOGY$2.6B$2.6B$2.6B———
Abiomed$748.3M$748.3M$748.3M———
other cardiovascular$190.0M$190.0M$190.0M———
SPINE,SPORTS & OTHER$1.5B$1.5B$1.5B———

% Change

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
ELECTROPHYSIOLOGY9.3%9.3%9.3%———
Abiomed11.6%11.6%11.6%———
other cardiovascular5.7%5.7%5.7%———
SPINE,SPORTS & OTHER-0.7%-0.7%-0.7%———

Geographic

Sales to customers (Note 9)

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Non Us$9.9B$9.6B$9.3B$9.6B$10.2B$10.3B
Europe$5.2B$4.9B$4.9B$5.1B$5.4B$5.4B
Asia Pacific Africa$3.5B$3.5B$3.3B$3.3B$3.6B$3.6B
Western Hemisphere Excluding US$1.2B$1.2B$1.1B$1.2B$1.2B$1.2B

Percent Change (as a percent)

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Non Us0.000.02—-0.020.030.08

Percent Change

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Europe0.020.04—-0.010.030.11
Western Hemisphere Excluding US0.070.00—-0.02-0.010.05
Asia Pacific Africa-0.040.01—-0.030.040.04

Long-Lived Assets

SegmentQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Europe——$27.3B———
Western Hemisphere Excluding US——$1.7B———
Asia Pacific Africa——$1.5B———

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.